Xospata is approved as a targeted anti-cancer drug

By Eo, Yun-Ho | translator Choi HeeYoung

21.07.15 06:00:15

가나다라 0

Korea's first FLT3 target drug, NCCN guideline 'Category 1' recommendation

It is available at major hospitals such as SNHU and SMC. The registration is required

The emergence of FLT3 targeted anticancer drugs is also causing new changes in the area of acute myeloid leukemia, which lacked treatment options.

Chronic Myeloid Leukemia (CML), which was considered incurable, has benefited many patients from the commercialization of the targeted anti-cancer drug Glivec(Imatinib), but Acute Myeloid Leukemia (AML) has relied on next-generation chemotherapy, despite being a life-threatening serious condition.

Astellas' FLT3 target anti-cancer drug "Xospata ( Gilteritinib fumarate)" has been approved by the MFDS as the first FLT3mut+ recurrence or nonresponsive AML target treatment.

AMLs are identified by individual chromosomes or genetic mut

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)